Mode
Text Size
Log in / Sign up
Phase 4 N=50 Randomized Single-blind Treatment

Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler

Nasolabial Folds

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Jan 2010
Primary outcome: Primary: Pain Score Using a 10-cm Visual Analog Pain Scale (1 = no Pain, 10 = Very Severe Pain) — 2.8; 6.6 cm

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Radiesse® Injectable Dermal Filler Mixed with Lidocaine (Device); Radiesse® Injectable Dermal Filler without Lidocaine (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Merz North America, Inc.
Primary completion
Dec 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Score Using a 10-cm Visual Analog Pain Scale (1 = no Pain, 10 = Very Severe Pain)
2.8; 6.6
PRIMARY
Patients With Clinically Significant Reduction in Pain
45; 0

Summary

To assess pain during nasolabial fold treatment using Radiesse® Injectable Dermal Filler mixed with lidocaine.

Eligibility Criteria

Inclusion Criteria

  • Is at least 18 years of age.
  • Is a candidate for nasolabial fold treatment using Radiesse.
  • Understands and accepts the obligation not to receive any other facial procedures in the lower half of the face for 1 month.
  • Understands and accepts the obligation to present for all scheduled follow-up visits and is logistically able to meet all study requirements.
  • Has approximately symmetrical nasolabial folds.

Exclusion Criteria

  • Has received any type of treatment or procedures including surgery in the nasolabial folds.
  • Has received neurotoxins in the lower half of the face in the past 6 months.
  • Has received hyaluronic acid, calcium hydroxylapatite (CaHA) or collagen injections in the lower half of the face within past 1 ½ years.
  • Has received polylactic acid, polymethyl methacrylate (PMMA), silicone or any other permanent filler in the lower half of the face.
  • Has nasolabial folds that are too severe to be corrected in one treatment session.
  • Has a history of chronic or recurrent infection or inflammation that would preclude participation in the study.
  • Has a known bleeding disorder or is receiving medication that will likely increase the risk of bleeding.
  • Is female and of child bearing potential and is pregnant or not using acceptable method of birth control.
  • Has had any history of hypersensitivity to Lidocaine or anesthetics of the amide type.
  • Has a history of anaphylaxis or multiple severe allergies.
  • Has received any investigational product within 30 days prior to study enrollment or is planning to participate in another investigation during the course of this study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01012661). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search